Pancreaticobiliary Neoplasm

In vivo genetic evidence for context-specific effector pathways of oncogenic Kras in PDAC and define cell autonomous Kras → PI3K → PDK1 signaling as a therapeutic target in pancreatic cancer. Targeti… (full text at CIViC)

PMID 23453624 · Eser et al., 2013 · Open in CIViC

A phase 1 dose‑escalation and dose‑expansion study in patients with previously treated advanced KRAS p.G12D mutant pancreatic ductal adenocarcinoma (NCT05382559; n = 203 overall; n = 21 PDAC treated a… (full text at CIViC)

PMID 41879829 · Park et al., 2026 · Open in CIViC

In an in vitro study, PLX-4032 cell lines expressing KRAS G12D mutation demonstrated resistance to vemurafenib treatment, compared to PDA_014 cell expressing BRAF V600E mutation (a known sensitizing m… (full text at CIViC)

PMID 25855536 · Witkiewicz et al., 2015 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring CDKN2A_p16 R80* and KRAS G12D, was treated with Palbocicl… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (82 y/F) with pancreatic cancer harboring GNAS R201C, KRAS G12D and, NF1 D1976fs, was treated with … (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (63 y/F) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (69 y/M) with pancreatic cancer harboring, CDKN2A exons 1-2 loss, CDKN2B loss, KRAS G12D, KRAS G12R… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastati… (full text at CIViC)

PMID 24915778 · Infante et al., 2014 · Open in CIViC

KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC)

PMID 24915778 · Infante et al., 2014 · Open in CIViC

In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28).

PMID 22983505 · Ogura et al., 2013 · Open in CIViC

In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (as well as G12D) was associated with poorer prognosis (95% confidence interval of HR between 1.11 and 2.28).

PMID 22983505 · Ogura et al., 2013 · Open in CIViC

An in vitro study shows that KRAS4A KO is significantly associated with reduced cell viability when cells are treated with KG5 (p < 0.0001). Moreover KRAS4A KO is significantly associated with reduced… (full text at CIViC)

PMID 34257283 · Chen et al., 2021 · Open in CIViC

An in vitro study shows that KRAS4A KO is significantly associated with reduced cell viability when cells are treated with KG5 (p < 0.0001). Moreover KRAS4A KO is significantly associated with reduced… (full text at CIViC)

PMID 34257283 · Chen et al., 2021 · Open in CIViC

Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC)

PMID 26725216 · Hayes et al., 2016 · Open in CIViC

The authors demonstrated that in contrast to the K-RasG12D or K-RasG12V mouse models, mice that express the K-RasV14I mutation at postnatal stages, either in all cells or only in the lungs, did not de… (full text at CIViC)

PMID 27174785 · Hernández-Porras et al., 2016 · Open in CIViC

10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH p… (full text at CIViC)

PMID 20088962 · Ojima et al., 2010 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with… (full text at CIViC)

PMID 26662432 · Li et al., 2015 · Open in CIViC

Notably, the antitumor efficacy of OMP-59R5 in combination with gemcitabine was significantly associated with expression of human Notch3 gene in pancreatic cancer. Tumors that were more sensitive to t… (full text at CIViC)

PMID 25934888 · Yen et al., 2015 · Open in CIViC

In preclinical pancreatic ductal adenocarcinoma (PDAC) models with high NQ01 expression, which indicates the NFE2L2 (NRF2) pathway activation, the small molecule NSC84167 (NSLC01, 50 mg/kg) selectivel… (full text at CIViC)

PMID 34247201 · Dai et al., 2021 · Open in CIViC

In pancreatic cancer cell lines MiaPaCa2 and Panc1, gemcitabine 1 μmol/L induced NR4A2/NURR1 expression and triggered cytoprotective autophagy, while both CRISPR-mediated NR4A2 knockout and the NR4A2 … (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

In a retrospective TCGA PDAC (tumors n = 179, normals n = 171), high ATG7 expression was significantly associated with poorer survival on Kaplan–Meier analysis (P = 0.013), and high ATG12 expression s… (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

Two patients with pancreatic adenocarcinoma harboring NRG1 gene fusions were treated with afatinib. Both of them showed a tumor response.

PMID 31068372 · Jones et al., 2019 · Open in CIViC

In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mito… (full text at CIViC)

PMID 21135251 · Villarroel et al., 2011 · Open in CIViC

For this single-arm phase II trial patients with locally advanced or metastatic pancreatic cancer (neuroendocrine excluded); and had a confirmed pathogenic or likely pathogenic germline (g) or somatic… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC)

PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC

siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), producing approximately 7-fold and 6-fold IC5… (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the CHK1 inhibitors LY2603618 and MK-8776, producing approximately 7-fold and 13-fold IC50 shifts, respectively, … (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC)

PMID 22025163 · Yap et al., 2011 · Open in CIViC

Whole-genome sequence analysis in a family with multiple cases of pancreatic ductal adenocarcinoma identified a germline RABL3 truncating mutation. RABL3 was associated with the regulation of the pren… (full text at CIViC)

PMID 31406347 · Nissim et al., 2019 · Open in CIViC

In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC)

PMID 11792751 · Plath et al., 2002 · Open in CIViC

The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM1 progressiv… (full text at CIViC)

PMID 17224927 · Nakano et al., 2007 · Open in CIViC

There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine. Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with … (full text at CIViC)

PMID 19543324 · Akita et al., 2009 · Open in CIViC

In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying g… (full text at CIViC)

PMID 17131328 · Nakahira et al., 2007 · Open in CIViC

The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM2 progressi… (full text at CIViC)

PMID 17224927 · Nakano et al., 2007 · Open in CIViC

In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concent… (full text at CIViC)

PMID 24088390 · Stenzinger et al., 2013 · Open in CIViC

Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC)

PMID 22705007 · Maréchal et al., 2012 · Open in CIViC

In this case report of a single patient with pancreatic adenocarcinoma was found to harbour a SLC4A4::ROS1 fusion by NGS analysis. Based on the presence of the ROS1 fusion the patient was initiated on… (full text at CIViC)

PMID 37079858 · Reutter et al., 2023 · Open in CIViC

In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC)

PMID 11751510 · Tascilar et al., 2001 · Open in CIViC

One of the goals in this study was to examine the correlation between Smad4 expression, detected by immunostaining, and the pattern of disease progression in pancreatic adenocarcinoma. Eleven of 15 (7… (full text at CIViC)

PMID 21709185 · Crane et al., 2011 · Open in CIViC

Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DP… (full text at CIViC)

PMID 19273710 · Iacobuzio-Donahue et al., 2009 · Open in CIViC

In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.

PMID 19584151 · Blackford et al., 2009 · Open in CIViC

In patients with Pancreatic Cancer, about half of them show an under expression of SMAD4. There was no relationship between SMAD4 expression and OS, but PFS was much longer in patients with SMAD4 unde… (full text at CIViC)

PMID 28534865 · Ormanns et al., 2017 · Open in CIViC

Using univariate analysis, the results showed that underexpression of SMAD4 had a strong relationship with poor OS in pancreatic cancer patients. More specifically, the underexpression of SMAD4 was re… (full text at CIViC)

PMID 26947875 · Shugang et al., 2016 · Open in CIViC